Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cells

Nature Reviews Clinical Oncology

Volumn 11, Issue 12, 2014, Pages 685-686

  Klebanoff, Christopher A ^a   Yamamoto, Tori N ^a   Restifo, Nicholas P ^a  

^a Laboratory of Molecular Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIBODY; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 7; T LYMPHOCYTE RECEPTOR; TOCILIZUMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; APHASIA; CANCER PATIENT; CANCER RECURRENCE; CELL BASED GENE THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONFUSION; CYTOKINE RELEASE SYNDROME; FEVER; FOLLICULAR LYMPHOMA; GAIT DISORDER; HUMAN; HYPOTENSION; INDOLENT LYMPHOMA; LARGE CELL LYMPHOMA; LYMPHOMA; MYOCLONUS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SHORT SURVEY; IMMUNOTHERAPY; METABOLISM; PROCEDURES; TREATMENT OUTCOME;

ANTIGENS, CD19; HUMANS; IMMUNOTHERAPY; LYMPHOMA; TREATMENT OUTCOME;

EID: 84927175337     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.190     Document Type: Short Survey

References (10)

1. Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550-4557 (2011).
2. Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2014.56.2025 (2014).
3. Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102 (2010).
4. Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720 (2012).
5. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
6. Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
7. Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).
8. Klebanoff, C. A., Khong, H. T., Antony, P. A., Palmer, D. C. & Restifo, N. P. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26, 111-117 (2005).
9. Klebanoff, C. A., Gattinoni, L. & Restifo, N. P. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J. Immunother. 35, 651-660 (2012).
10. Gattinoni, L., Klebanoff, C. A. & Restifo, N. P. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12, 671-684 (2012).